Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial

详细信息    查看全文

• 作者：Douglas L. Arnold ; Peter A. Calabresi ; Bernd C. Kieseier ; Shifang Liu…
• 关键词：Clinical trial ; Phase 3 ; Multiple sclerosis ; Relapse ; remitting multiple sclerosis ; Peginterferon beta ; 1a ; Pegylation ; Interferon ; Magnetic resonance imaging ; NEDA ; No evidence of disease activity
• 刊名：BMC Neurology
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：17
• 期：1
• 全文大小：924KB
• 刊物主题：Neurology; Neurochemistry; Neurosurgery;
• 出版者：BioMed Central
• ISSN：1471-2377
• 卷排序：17

文摘

BackgroundSubcutaneous peginterferon beta-1a has previously been shown to reduce the number of T2-hyperintense and gadolinium-enhancing (Gd+) lesions over 2 years in patients with relapsing-remitting multiple sclerosis (RRMS), and to reduce T1-hypointense lesion formation and the proportion of patients showing evidence of disease activity, based on both clinical and radiological measures, compared with placebo over 1 year of treatment. The objectives of the current analyses were to evaluate T1 lesions and other magnetic resonance imaging (MRI) measures, including whole brain volume and magnetization transfer ratio (MTR) of normal appearing brain tissue (NABT), and the proportions of patients with no evidence of disease activity (NEDA), over 2 years.